---
title: Tofersen decreases neurofilament levels supporting the pathogenesis of the
  SOD1 p.D91A variant in amyotrophic lateral sclerosis patients
date: '2024-07-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39054363/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240726183330&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: The finding is relevant for decision making regarding tofersen
  treatment, patient counseling and inclusion of SOD1^(D91A) patients in drug trials.
  As far as we are aware, the approach is conceptually new since it provides evidence
  for the causality of an ALS variant based on a biomarker response to gene-specific
  ...'
disable_comments: true
---
CONCLUSIONS: The finding is relevant for decision making regarding tofersen treatment, patient counseling and inclusion of SOD1^(D91A) patients in drug trials. As far as we are aware, the approach is conceptually new since it provides evidence for the causality of an ALS variant based on a biomarker response to gene-specific ...